List: Medicare deal will lower the prices of these drugs
In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. (Photo Illustration by Scott Olson/Getty Images)
WASHINGTON - Ten popular prescription drugs will soon become cheaper for Medicare recipients, according to the White House. The full list was released Thursday morning and it includes drugs to treat diabetes, blood clots, and other conditions.
The prices come as a result of negotiations with drug manufacturers. For decades, the federal government had been barred from bartering with pharmaceutical companies over the price of their drugs – even though it's a routine process for private insurers. But the Inflation Reduction Act gave the government that ability, and the White House announced the first results this week.
Biden administration officials said Wednesday night that they expect U.S. taxpayers to save $6 billion with the new prices, while older Americans could save roughly $1.5 billion on their medications.
Full list: Drugs with new lower prices
These new prices will go into effect for people with Medicare Part D prescription drug coverage in 2026.
Eliquis
- What it treats: Prevention and treatment of blood clots
- Manufacturer: Bristol Myers Squibb
- Medicare enrollees who used drug in 2023: 3,928,000
- 2023 price for 30-day supply: $521
- 2026 price for 30-day supply: $231
- Savings: $290 (-56%)
Jardiance
- What it treats: Diabetes; Heart failure; Chronic kidney disease
- Manufacturer: Boehringer Ingelheim
- Medicare enrollees who used drug in 2023: 1,883,000
- 2023 price for 30-day supply: $573
- 2026 price for 30-day supply: $197
- Savings: $376 (-66%)
Xarelto
- What it treats: Prevention and treatment of blood clots; Reduction of risk for patients with coronary or peripheral artery disease
- Manufacturer: Janssen Pharms
- Medicare enrollees who used drug in 2023: 1,324,000
- 2023 price for 30-day supply: $517
- 2026 price for 30-day supply: $197
- Savings: $320 (-62%)
Januvia
- What it treats: Diabetes
- Manufacturer: Merck Sharp Dohme
- Medicare enrollees who used drug in 2023: 843,000
- 2023 price for 30-day supply: $527
- 2026 price for 30-day supply: $113
- Savings: $414 (-79%)
Farxiga
- What it treats: Diabetes; Heart failure; Chronic kidney disease
- Manufacturer: AstraZeneca AB
- Medicare enrollees who used drug in 2023: 994,000
- 2023 price for 30-day supply: $556
- 2026 price for 30-day supply: $178.50
- Savings: $377.50 (-68%)
Entresto
- What it treats: Heart failure
- Manufacturer: Novartis Pharms Corp
- Medicare enrollees who used drug in 2023: 664,000
- 2023 price for 30-day supply: $628
- 2026 price for 30-day supply: $295
- Savings: $333 (-53%)
Enbrel
- What it treats: Rheumatoid arthritis; Psoriasis; Psoriatic arthritis
- Manufacturer: Immunex Corporation
- Medicare enrollees who used drug in 2023: 48,000
- 2023 price for 30-day supply: $7,106
- 2026 price for 30-day supply: $2,355
- Savings: $4,751 (-67%)
Imbruvica
- What it treats: Blood cancers
- Manufacturer: Pharmacyclics LLC
- Medicare enrollees who used drug in 2023: 17,000
- 2023 price for 30-day supply: $14,934
- 2026 price for 30-day supply: $9,319
- Savings: $5,615 (-38%)
Stelara
- What it treats: Psoriasis; Psoriatic arthritis; Crohn's disease; Ulcerative colitis
- Manufacturer: Janssen Biotech, Inc.
- Medicare enrollees who used drug in 2023:
- 2023 price for 30-day supply: $13,836
- 2026 price for 30-day supply: $4,695
- Savings: $9,141 (-66%)
Fiasp, Fiasp FlexTouch, Fiasp PenFil, NovoLog, NovoLog FlexPen, NovoLog PenFill
- What it treats: Diabetes
- Manufacturer: Novo Nordisk Inc.
- Medicare enrollees who used drug in 2023: 785,000
- 2023 price for 30-day supply: $495
- 2026 price for 30-day supply: $119
- Savings: $376 (-76%)
Medicare will select up to 15 additional drugs covered under Part D for negotiation in 2025, up to an additional 15 Part B and D drugs in 2026, and up to 20 drugs every year after that.